#Exchange Offer #Denmark #Lundbeck #Valby #Lundbeckfond

Lundbeckfond Invest A/S Initiates Voluntary Exchange Offer for A-Shares in H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical firm known for its focus on brain health, has announced a significant development regarding its share structure. Recently, Lundbeckfond Invest A/S, a wholly-owned subsidiary of the Lundbeck Foundation and a prominent shareholder of Lundbeck, initiated a voluntary exchange offer. This offer is specifically directed towards eligible A-shareholders of H. Lundbeck, presenting a notable opportunity for investors.

The voluntary exchange offer allows shareholders to exchange their A-shares in Lundbeck for potentially favorable terms and conditions that Lundbeckfond Invest has laid out. This announcement, made in Valby, Denmark, emphasizes Lundbeckfond Invest’s commitment to fostering shareholder engagement and strengthening Lundbeck’s capital base. It reflects the ongoing efforts from Lundbeck to enhance its financial strategy amidst evolving market dynamics.

According to Lundbeck, the details of the exchange offer, including the terms and conditions, can be found on their dedicated website, where potential participants can also find additional relevant information and contact details for inquiries. The largest shareholder of Lundbeck has indicated its intention to participate in this exchange offer, utilizing its existing holding of A-shares, thereby reinforcing its position within the company.

However, it's important to note that the shares of Lundbeck are not registered under the U.S. Securities Act of 1933, which means they may not be offered or sold in the United States unless specific registration or exemption requirements are met. This stipulation highlights the regulatory landscape surrounding international stock offerings and the adherence to compliance standards within the investing community.

About H. Lundbeck A/S

H. Lundbeck A/S has a longstanding legacy of over 70 years, concentrating primarily on brain health and the treatment of neurological disorders. The company is dedicated to improving the quality of life for individuals suffering from psychiatric and neurological diseases, which are prevalent across the global population.

As a focused innovator, Lundbeck aims to advance its research and development efforts to find viable solutions to complex neurological challenges. Their mission is to develop transformative medicines that cater to those lacking adequate treatment alternatives, expanding their specialization into neuro-specialty and neuro-rare domains — a marked departure from their traditional focus on psychiatry and neurology.

In addition to its innovative pursuits, Lundbeck also champions the fight against stigma associated with mental health and strives to enhance health equity. The company recognizes its role in creating long-term value for its shareholders while positively impacting patients, families, and society as a whole. With a workforce exceeding 5,000 employees spread across over 20 countries, Lundbeck's products reach more than 80 countries, underscoring its significant global presence in the pharmaceutical industry.

For those interested in the exchange offer, Lundbeck encourages further engagement via its corporate website and social media channels to stay updated on the latest news and announcements. This initiative marks another step in Lundbeck's journey towards strengthening its financial foundation and reinforces its dedication to the well-being of its investors and the communities they serve.

In conclusion, Lundbeckfond Invest A/S's voluntary exchange offer represents a pivotal moment for eligible A-shareholders of H. Lundbeck, and investors may wish to partake in this opportunity to engage further with the company in shaping its future developments.